Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
NCT06240728 · View on ClinicalTrials.gov ↗
Study Summary
NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (HHLA2) expressing tumors at selected dose(s). The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? * what is the preliminary anti-tumor activities? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treating physicians.
Conditions Studied
Interventions
- DRUG NPX887
Study Locations (8)
Texas
- MD Anderson Cancer Center — Houston
- Next Oncology — San Antonio
Other
- Severance Hospital, Yonsei University Health System — Seoul
- Samsung Medical Center — Seoul
Maryland
- Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center — Baltimore
Massachusetts
- Beth Israel Deaconess Medical Center (BIDMC) — Boston
New York
- Albert Einstein Medical College Montefiore Medical Center — The Bronx
Virginia
- NEXT Oncology-Fairfax — Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06240728
The ClinicalTrials.gov registry entry for NCT06240728 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NextPoint Therapeutics, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Metastatic Malignant Neoplasm appearing as the primary indexed condition, and to 1 intervention — of which NPX887 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06240728 reports 8 study locations spanning 6 distinct geographic areas — top geographies include Texas, Other, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06240728 about?
NCT06240728 is a clinical study titled "A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2". NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (...
What is the current status of trial NCT06240728?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2024-01-22. Estimated completion is 2027-08.
What conditions does trial NCT06240728 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06240728?
The interventions under investigation include: NPX887 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06240728?
This trial is sponsored by NextPoint Therapeutics, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06240728 being conducted?
This trial has 8 study locations across Maryland, Massachusetts, New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.